- Investing.com
Metrics to compare | BPTSY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBPTSYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −2.4x | −0.5x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | −0.3x | −0.8x | 2.6x | |
Price / LTM Sales | - | 24.0x | 3.2x | |
Upside (Analyst Target) | - | 171.6% | 50.8% | |
Fair Value Upside | Unlock | 8.4% | 7.7% | Unlock |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.